Jazz Pharmaceuticals : Submission of Matters to a Vote of Security Holders (Form 8-K)

Submission of Matters to a Vote of Security Holders.

On September 23, 2021, Jazz Pharmaceuticals plc (the "Company") held an extraordinary general meeting of its shareholders, or EGM, at the Company's corporate headquarters located at Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4, Ireland. The EGM was held for two proposals, both of which are described in more detail in the Company's definitive proxy statement on Schedule14A as filed with the SEC on August 30, 2021. The results of the matters presented at the EGM, based on the presence in person or by proxy of holders of 49,842,702 of the 61,363,973 ordinary shares entitled to vote, are described below.

Proposal 1

Proposal 1 was to grant the board of directors authority under Irish law to allot and issue ordinary shares for cash without first offering those ordinary shares to existing shareholders pursuant to the statutory pre-emptionright that would otherwise apply. This proposal required the affirmative vote of 75% of the votes cast on the proposal and was approved as follows:

For		Against		Abstain		Broker Non-Votes
49,570,440		253,301		18,961		-

Proposal 2

Proposal 2 was to approve any motion to adjourn the EGM, or any adjournments thereof, to another time and place to solicit additional proxies if there are insufficient votes at the time of the EGM to approve Proposal 1. As no motion to adjourn the EGM was made, Proposal 2 was not put to a vote of the shareholders at the EGM.